RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: A marker of ER-positive luminal-like subtype

Breast Cancer Research and Treatment

Volumn 128, Issue 2, 2011, Pages 315-326

  Habashy, Hany Onsy ^a,b   Powe, Desmond G ^c   Glaab, Enrico ^d   Ball, Graham ^e   Spiteri, Inmaculada ^f   Krasnogor, Natalio ^d   Garibaldi, Jonathan M ^d   Rakha, Emad A ^a   Green, Andrew R ^a   Caldas, C ^f   Ellis, Ian O ^a,d  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b MANSOURA UNIVERSITY   (Egypt)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Breast carcinoma; Gene expression; Immunohistochemistry; Luminal; Oestrogen receptor; RERG

Indexed keywords

ANDROGEN RECEPTOR; BRCA1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; ESTROGEN RECEPTOR; FRAGILE HISTIDINE TRIAD PROTEIN; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; MESSENGER RNA; PROTEIN P53; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GENETICS; CANCER GRADING; CANCER INVASION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FEMALE; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MARKER GENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RERG GENE; VALIDATION STUDY;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; GENE EXPRESSION PROFILING; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 79959735521     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1073-y     Document Type: Article

References (28)

1. CM Perou T Sorlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
2. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications PNAS 98 19 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
3. C Sotiriou SY Neo LM McShane EL Korn PM Long A Jazaeri P Martiat SB Fox AL Harris ET Liu 2003 Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 18 10393 10398 12917485 10.1073/pnas.1732912100 1:CAS:528:DC%2BD3sXntFynsrk%3D (Pubitemid 37071889)
4. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler, et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 14 8418 8423 12829800 10.1073/pnas.0932692100 1:CAS:528:DC%2BD3sXlsFGntLk%3D (Pubitemid 36842560)
5. H Habashy D Powe E Rakha G Ball R Macmillan A Green I Ellis 2010 The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype Breast Cancer Res Treat 120 3 603 612 19495959 10.1007/s10549-009-0419-9 1:CAS:528:DC%2BC3cXjs1ajtbs%3D
6. H Habashy D Powe C Staka E Rakha G Ball A Green M Aleskandarany E Paish R Douglas Macmillan R Nicholson, et al. 2010 Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen Breast Cancer Res Treat 119 2 283 293 19238537 10.1007/s10549-009-0345-x 1:CAS:528:DC%2BD1MXhsFyjs7fL
7. HO Habashy DG Powe EA Rakha G Ball C Paish J Gee RI Nicholson IO Ellis 2008 Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance Eur J Cancer 44 11 1541 1551 18538561 10.1016/j.ejca.2008.04.020 1:CAS:528:DC%2BD1cXotlClsb0%3D
8. LJ Lancashire RC Rees GR Ball 2008 Identification of gene transcript signatures predictive for estrogen receptor and lymph node status using a stepwise forward selection artificial neural network modelling approach Artif Intell Med 43 2 99 111 18420392 10.1016/j.artmed.2008.03.001
9. DE Rumelhart GE Hinton RJ Williams 1986 Learning representations by back-propagating errors Nature 323 6088 533 536 10.1038/323533a0 (Pubitemid 16025374)
10. L Lancashire D Powe J Reis-Filho E Rakha C Lemetre B Weigelt T Abdel-Fatah A Green R Mukta R Blamey, et al. 2010 A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks Breast Cancer Res Treat 120 1 83 93 19347577 10.1007/s10549-009-0378-1 1:STN:280:DC%2BC3c%2FivVGhug%3D%3D
11. BS Finlin CL Gau GA Murphy HP Shao T Kimel RS Seitz YF Chiu D Botstein PO Brown F Tamanoi, et al. 2001 RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer J Biol Chem 276 45 42259 42267 11533059 10.1074/jbc.M105888200 1:CAS:528:DC%2BD3MXosVGmsrY%3D (Pubitemid 37371136)
12. S Chin A Teschendorff J Marioni Y Wang N Barbosa-Morais N Thorne J Costa S Pinder M van de Wiel A Green, et al. 2007 High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer Genome Biol 8 10 R215 17925008 10.1186/gb-2007-8-10-r215 (Pubitemid 351917462)
13. C Blenkiron L Goldstein N Thorne I Spiteri S-F Chin M Dunning N Barbosa-Morais A Teschendorff A Green I Ellis, et al. 2007 MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype Genome Biol 8 10 R214 17922911 10.1186/gb-2007-8-10-r214 (Pubitemid 351917463)
14. H Zhang E Rakha G Ball I Spiteri M Aleskandarany E Paish D Powe R Macmillan C Caldas I Ellis, et al. 2010 The proteins FABP7 and OATP2 are associated with the basal phenotype and patient outcome in human breast cancer Breast Cancer Res Treat 121 1 41 51 19590950 10.1007/s10549-009-0450-x 1:CAS:528:DC%2BC3cXkvVymtL8%3D
15. DM Abd El-Rehim G Ball SE Pinder E Rakha C Paish JFR Robertson D Macmillan RW Blamey IO Ellis 2005 High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses Int J Cancer 116 3 340 350 15818618 10.1002/ijc.21004 1:CAS:528:DC%2BD2MXmtl2ktb0%3D (Pubitemid 40993329)
16. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article3
17. R Tibshirani T Hastie B Narasimhan G Chu 2002 Diagnosis of multiple cancer types by shrunken centroids of gene expression Proc Natl Acad Sci USA 99 10 6567 6572 12011421 10.1073/pnas.082099299 1:CAS:528:DC%2BD38XjvFCktbg%3D (Pubitemid 34526173)
18. E Glaab J Garibaldi N Krasnogor 2009 ArrayMining: a modular web-application for microarray analysis combining ensemble and consensus methods with cross-study normalization BMC Bioinformatics 10 1 358 19863798 10.1186/1471-2105-10-358
19. IO Ellis M Galea N Broughton A Locker RW Blamey CW Elston 1992 Pathological prognostic factors in breast-cancer. 2. Histological type-relationship with survival in a large study with long-term follow-up Histopathology 20 6 479 489 1607149 10.1111/j.1365-2559.1992.tb01032.x 1:STN:280:DyaK383pvFartw%3D%3D
20. CW Elston IO Ellis 1991 Pathological prognostic factors in breast-cancer. 1. The value of histological grade in breast-cancer-experience from a large study with long-term follow-up Histopathology 19 5 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
21. MH Galea RW Blamey CE Elston IO Ellis 1992 The Nottingham prognostic index in primary breast-cancer Breast Cancer Res Treat 22 3 207 219 1391987 10.1007/BF01840834 1:STN:280:DyaK3s%2FgsVyisA%3D%3D
22. Z Madjd SE Pinder C Paish IO Ellis J Carmichael LG Durrant 2003 Loss of CD59 expression in breast tumours correlates with poor survival J Pathol 200 5 633 639 12898600 10.1002/path.1357 1:CAS:528:DC%2BD3sXntl2nurc%3D (Pubitemid 36987313)
23. EA Rakha ME El-Sayed AH Lee CW Elston MJ Grainge Z Hodi RW Blamey IO Ellis 2008 Prognostic significance of Nottingham histologic grade in invasive breast carcinoma J Clin Oncol 26 19 3153 3158 18490649 10.1200/JCO.2007.15.5986
24. MH Galea RW Blamey CE Elston IO Ellis 1992 The Nottingham prognostic index in primary breast cancer Breast Cancer Res Treat 22 3 207 219 1391987 10.1007/BF01840834 1:STN:280:DyaK3s%2FgsVyisA%3D%3D
25. EA Rakha SE Elsheikh MA Aleskandarany HO Habashi AR Green DG Powe ME El-Sayed A Benhasouna JS Brunet LA Akslen, et al. 2009 Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes Clin Cancer Res 15 7 2302 2310 19318481 10.1158/1078-0432.CCR-08-2132 1:CAS:528:DC%2BD1MXjvVWltbs%3D
26. MA Aleskandarany AR Green EA Rakha RA Mohammed SE Elsheikh DG Powe EC Paish RD Macmillan S Chan SI Ahmed, et al. 2010 Growth fraction as a predictor of response to chemotherapy in node-negative breast cancer Int J Cancer 126 7 1761 1769 19711345 1:CAS:528:DC%2BC3cXhtl2it70%3D
27. DM Abd El-Rehim SE Pinder CE Paish JA Bell RS Rampaul RW Blamey JFR Robertson RI Nicholson IO Ellis 2004 Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma Br J Cancer 91 8 1532 1542 15480434 10.1038/sj.bjc.6602184 1:CAS:528:DC%2BD2cXotlCkurk%3D (Pubitemid 39486359)
28. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 229 235 16932852 10.1007/s10549-006-9242-8 (Pubitemid 44631925)